usdt官网接【jie】口《kou》www.trc20.vip)是使用TRC-20协议{yi}的「de」Usdt第三方支『zhi』付平‘ping’台“tai”,Usdt收款平《ping》台、Usdt自动充提「ti」平台『tai』。免费提供入金「jin」通道、Usdt钱{qian}包支 zhi[付接口、Usdt自动 dong[充值“zhi”接“jie”口、Usdt寄《ji》售『shou』回收。菜宝Usdt钱包一(yi)键生成Usdt钱包、一键『jian』调 diao[用《yong》API接口〖kou〗、一‘yi’键“jian”出{chu}售‘shou’Usdt。

,“The gradual rise in consumer healthcare sales mix in the medium term will likely dilute the overall margins slightly, given the segment’s lower margin owing to its higher advertising and promotion costs,” CGS-CIMB Research said in its latest report.

KUALA LUMPUR: Pharmaniaga Bhd’s profit margins could see some pressures ahead on higher input costs.

The group noted in its recent briefing with *** ysts that higher input costs may potentially be felt from higher active pharmaceutical ingredient prices and the weaker ringgit to US dollar.

However, it said these factors have had a minimal impact so far on its margins, noting that this could change if the situation continues over the next three months or longer.

“The gradual rise in consumer healthcare sales mix in the medium term will likely dilute the overall margins slightly, given the segment’s lower margin owing to its higher advertising and promotion costs,” CGS-CIMB Research said in its latest report.

The research house has lowered its earnings before interest, taxes, depreciation and amortisation (Ebitda) margins forecast for Pharmaniaga slightly and expects Ebitda margin for the financial year 2022 (FY22) to contract by 3.3 percentage points to 4.6%.

“We believe our cuts sufficiently reflect the potential input cost pressures ahead,” it said.

Due to this, the research house had also cut its forecast core earnings per share for FY22-FY24 by 6% to 7.5% to factor in lower Ebitda margins and higher FY23-FY24 forecast capital expenditures for new warehouses.

CGS-CIMB Research had maintained its “add” rating on the stock but cut its target price to 73 sen, which is based on 15 times forecast price-to-earnings ratio for 2023.

Meanwhile, Pharmaniaga hopes to double or even triple its consumer healthcare revenue contribution by FY24 from a low base or less than 1% of revenue so far.

This would be supported by new product launches, which would help offset a normalisation in Vitamin C demand that was boosted by the Covid-19 surge prior to this.

“It is also exploring possible acquisitions of brands with established product ranges and customer base to expedite the consumer healthcare expansion and it has not factored this into its revenue target,” it added.

Pharmaniaga’s manufacturing plant for oral solid dosages in Bangi, Selangor, is operating at a utilisation rate of about 65%, which gives it room to ramp up output if the need arises.

“We believe the ample excess production capacity at Pharmaniaga’s existing plants will give it space for more output in the next three to five years on rising pharmaceutical demand and new product launches,” CGS-CIMB Research said.

Demand can be met with little to no incremental capital expenditures, it said.

Usdt自动充值接口声明:该文看法仅代表作者自己,与本平台无关。转载请注明:usdt官网接口(www.trc20.vip)_Pressure on Pharmaniaga margins
发布评论

分享到:

足球预测专家(www.99cx.vip)_英(ying)皇《huang》在港首设戏“xi”院 利雅博乐掌门人
1 条回复
  1. 皇冠最新线路(www.hg9988.vip)
    皇冠最新线路(www.hg9988.vip)
    (2022-07-04 15:31:12) 1#

    戴伟浚“作为职业球员,无论什么情况,需要顶着压力做好自己,自己要自律,做自己该做的事情。”我是铁粉,可以提问我

发表评论

◎欢迎参与讨论,请在这里发表您的看法、交流您的观点。